Answers are grounded in this paper and cite their sources.
(Molecular Therapy 25, 259–273; January 4, 2017) The authors regret that King’s Health Partners Confidence in Concept was inadvertently omitted as a funding source in the Acknowledgments section of the original paper. The corrected Acknowledgments section appears below and has been corrected online. We apologize for any inconvenience this may have caused. This research was supported by Worldwide Cancer Research (13- 1017), Breast Cancer Now (2010MayPR33), Pancreatic Cancer UK (A16648), King’s Health Partners Confidence in Concept (MC_PC_14105), the Experimental Cancer Medicine Centre at King’s College London, and by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We thank Anthony Walker and Mike Garrison for useful discussions. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T CellsWhilding et al.Molecular TherapyDecember 8, 2016In BriefMaher and colleagues describe a chimeric antigen receptor (CAR) directed against the αvβ6 integrin, a target that is aberrantly expressed in diverse solid tumors but that exhibits highly restricted expression in normal tissues. αvβ6-re-targeted CAR T cells elicit therapeutic activity in several tumor models while maintaining an excellent safety profile.
No takes yet. Share an insight, caveat, or question.
Whilding et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: